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Abstract
Inflammatory bowel disease, especially Crohn disease, had increased in the last five decades. We analyzed all the 
patients of our unit diagnosed with the disease between 2001-2012 but we just considered the patients who respected 
the Porto criteria to define IBD at presentation. We diagnosed 51 children and adolescents with the disease. Crohn 
disease was responsible for 62.7% of cases, ulcerative colitis for 31.4% and indeterminate colitis for 5.9%. Considering 
the 4 different periods of time (2001-2003/2004-2006/2007-2009 and 2010-2012), we observed and increase in the 
number of cases, but a decrease in the time from onset of symptoms to diagnosis. 
Our medical approach with tumor necrosis factor antagonists was reserved for severe disease cases and to spare 
patients from adverse effects of purine analogues and corticosteroids. Mucosal healing and remission of the disease 
was achieved in all of the patients under biologic therapy and no serious or life-threating event was reported with their 
use.
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Introduction 
Inflammatory Bowel Disease (IBD) represents a heterogeneous 
group of chronic diseases, diagnosed before the age of 20 years in 25% 
to 30% of cases [1-3]. Recent epidemiological studies have shown an 
increasing incidence of IBD in the last five decades. Crohn Disease 
(CD), more than Ulcerative Colitis (UC) and Indeterminate Colitis 
(IC), is the major responsible for this upraising of pediatric cases [3-6]. 
The use of biologic therapy (tumor necrosis factor antagonists) is 
becoming a safe and more advocated strategy to manage pediatric IBD 
[7-12]. 
Methods
Retrospective study of the medical patients’ files diagnosed with 
IBD, between 2001-2012, and followed in the pediatric gastroenterology 
consultation at Hospital de Braga (HB). ESPGHAN (European Society 
for Paediatric Gastroenterology, Hepatology and Nutrition) established 
the Porto Criteria in July 2005. The recommendations include: total 
colonoscopy with ileal intubation; upper endoscopy; multiple biopsies 
and complete small bowel exploration. In our study, four different 
periods of time were analyzed: 2001-2003/2004-2006/2007-2009 and 
2010-2012. We just considered the patients who respected the Porto 
Criteria to define IBD [2]. The patients diagnosed before July 2005 that 
completed the recommendations during the evaluation were included. 
The following variables were studied: characterization of IBD, 
sex, family history, age at diagnosis, time from onset of symptoms 
to diagnosis, clinical presentation, extra intestinal manifestations, 
laboratory data and treatment options. Endoscopy with multiple 
biopsies for histology was performed to differentiate CD from UC and 
determine the extent of inflammation. 
Results
IBD was diagnosed in 51 children and adolescents, between 2001-
2012 at Hospital de Braga. CD was responsible for 62.7% (n=32) of 
cases, UC for 31.4% (n=16) and IC for 5.9% (n=3) (Table 1). The three 
patients with IC were younger than 10 years old. The patients’ gender 
(♂/♀) distribution per type of IBD was the following: CD (20♂/12♀), 
UC (5♂/11♀) and IC (2♂/1♀). The age at diagnosis varied between 6 
and 17 years of old, with a median age of 12 years. Family history of 
IBD was present in 17.6% (n=9) children. CD was present in six family 
members and UC in three.
The periods of times between 2007-2009 and 2010-2012 were 
the periods with more diagnosed cases, but they corresponded to the 
periods when the time from onset of symptoms to diagnosis was shorter, 
even if this difference was not statistically significant (ρ>0.01); However 
the gastroenterology unit, had a relatively constant mean number of 
consultations every 2-3 months to achieve diagnosis (Table 1).
The symptoms at time of presentation were variable, with 
abdominal pain present in 82.3% (n=42) of patients, diarrhea in 62.7% 
(n=32), hematoquezia or rectal bleeding in 35.3% (n=18), weight loss 
in 25.5% (n=13), lethargy in 23.5% (n=12), anorexia in 17.6% (n=9), 
fever in 9.8% (n=5), nausea or vomiting in 7.8% (n=4) and oral ulcers 
in 1.9% (n=1). 
Extra intestinal manifestations were reported in 21.6% (n=11) of 
patients (Table 2). 
The extent of inflammatory disease was determined and ileocolitis 
Patients/periods of time 2001-2003 2004-2006 2007-2009 2010-2012
CD (n=32) 12.5% 12.5% 34.4% 40.6%
UC (n=16) 0% 43.8% 37.5% 18.8%
IC (n=3) 0% 0% 66.7% 33.3%
Mean time to diagnosis 
(months): ρ=0.213
11.5 7.5 5.1 3.1
Mean number of 
consultations to diagnosis
1.75 2 1.47 1.53
Legend: CD (Crohn Disease); UC (Ulcerative Colitis); ID (Indeterminate Colitis) 
Table 1: Number of patients diagnosed with IBD per period of time.
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was the most frequent type in CD. It represented 84.4% (n=27) patients. 
Isolated terminal ileum inflammation was present in 9.4% (n=3) CD 
patients and colitis in 6.2% (n=2). Upper endoscopy found giant cell 
granulomas and aphthoid ulcers in 15.6% (n=5) CD patients, even if 
only three of these had upper gastrointestinal symptoms. Gastritis was 
detected in 25% (n=8) and anal disease was present in 25% (n=8) CD 
patients.
In the group of UC, pancolitis was the most prevalent type, with 
87.5% (n=14) patients, followed by distal colitis in 12.5% (n=2). 
Proctitis was not present in our UC group and backwash ileitis was 
diagnosed in 18.8% (n=3) of patients. 
Reduced level of hemoglobin (Hb<11.0 g/dl) was present in 39.2% 
(n=20) patients, eleven of them with CD and nine with UC. Raised 
markers of inflammation (erythrocyte sedimentation rate, C-reactive 
protein) were present in 86.3% (n=44) of patients. Ferritin level at 
presentation was checked in 29 children and it had a value <15 ng/
ml in 24.1% (n=7), two of them with CD, four with UC and one with 
IC. IgA or IgG anti-Saccharomyces cerevisiae antibodies (ASCA) 
were positive in 46.9% CD patients and perinuclear anti-neutrophil 
cytoplasmic antibody (p-ANCA) in 6.3% UC patients. In CD patients, 
(ASCA+/pANCA-) presented a sensitivity and specificity of 57.7% and 
93.8%, respectively. The combination of (ASCA-/pANCA+) displayed 
sensitivity of 25% and specificity of 100% for UC diagnosis. 
The medical treatment, besides the symptomatic and supportive 
therapy, to induce remission depended mainly on the use of 
corticosteroids (Table 3). The prevention of disease flares was achieved 
in our pediatric population with the use of azathioprine in the majority 
of CD patients and with an almost equivalent use of aminosalicylates 
and immunomodulators in UC patients (Table 4). Methotrexate was 
used only in a CD adolescent with polyarticular Juvenile Idiopathic 
Arthritis (JIA). 
The management with biologic agents to maintain remission 
was performed in 27.5% (n=14) patients, twelve of them were under 
infliximab periodic infusions and the other two were submitted to 
adalimumab therapy (Table 4). We do report four hypersensitive 
reactions to infliximab periodic infusions controlled with 
acetaminophen and antihistamic therapy. 
A step-up medical approach was conducted in the majority of 
our patients, with the exception of two severe disease cases where we 
preferred an earlier use of anti-TNF (antitumor necrosis factor) agents 
to induce and maintain remission (Tables 3 and 4). The two cases 
corresponded to two fistulizing CD patients. The other 12 cases that 
needed biologic therapy were previously under azathioprine, but eight 
of them did not achieve remission with the purine analogue and four 
developed side effects. We report two patients with gastrointestinal side 
effects (nausea and vomiting), one patient with anemia and another one 
with acute pancreatitis attributable to azathioprine.
Surgical management after the diagnosis of IBD was needed in two 
patients with CD. A fistulectomy was done to a patient with severe anal 
disease and an ileal resection was performed in one of the patients with 
fistulizing disease. 
Discussion
We detected an increase of IBD cases during the period of 2001-
2012, with a significant increase of CD. This type was more frequent in 
boys and UC was more prevalent in girls.
Considering the different periods of time, we can say that the 
unit progressively diagnosed more cases and that the time to achieve 
diagnosis was shorter. This could be due to an increase of experience 
of the members but also to the scientific reunions and formation 
meetings that the unit gave to general practitioners who are responsible 
for the referring of patients. In our opinion, we verified an increase 
of knowledge about pediatric IBD among the medical community 
of our region, reflected in a shorter time to achieve diagnosis and at 
the same time an equivalent mean number of consultations of the 
gastroenterology unit. 
The periods of times between 2007-2009 and 2010-2012 were 
the periods with more diagnosed cases, but they corresponded to 
the periods when the time from onset of symptoms to diagnosis was 
shorter, even if this difference was not statistically significant (ρ>0.01); 
However the gastroenterology unit, had a constant mean number of 
consultations every 2-3 months to achieve diagnosis.
Abdominal pain was the most frequent complain of our group 
of patients and arthritis was our most common extra intestinal 
manifestation. Ileocolitis and pancolitis were the most common forms 
of CD and UC respectively. 
Corticosteroids were the drugs of choice, in the majority of cases, 
to induce remission of bowel inflammation and azathioprine the most 
chosen therapy to maintain remission and prevent flare ups. Our 
medical approach with anti-TNF agents was reserved for the most 
severe cases, to maintain remission after azathioprine failure and to 
spare the patients to some adverse effects of purine analogues and to 
stop corticosteroids. We do not report any serious or life-threating 
event with the use of biologic agents. 
Extra intestinal manifestations 
(n=11)
CD 
(n=8)
UC 
(n=3)
Arthritis 62.5% 33.3%
Episcleritis 25% 0%
Autoimmune thyroiditis 12.5% 0%
Primary sclerosing cholangitis 0 33.3%
Autoimmune hepatitis 0 33.3%
Legend: CD (Crohn Disease); UC (Ulcerative Colitis) 
Table 2: Number of extra intestinal manifestations among our IBD patients.
Treatment of acute flares 
Induction of remission
CD 
n=32
UC 
n=16
IC 
n=3
Aminosalicylates 0% 31.3% 66.7%
Corticosteroids 96.9% 12.5% 33,3%
Aminosalicylates and 
Corticosteroids
3.1% 56.3% 0%
Anti-TNF agents 6.3% 0% 0%
Legend: CD (Crohn Disease); UC (Ulcerative Colitis); ID (Indeterminate Colitis) 
Anti-TNF (antitumor necrosis factor) 
Table 3: Therapy used for treatment of acute flares and to induce remission.
Prevention of acute flares 
Maintenance of remission
CD 
n=32
UC 
n=16
IC 
n=3
Aminosalicylates 0% 56.3% 100%
Immunomodulators 
(azathioprine/methotrexate)
93.8% 43.8% 0%
Anti-TNF agents (infliximab/ 
adalimumab)
34.4% 6.3% 
(only anti-TNF)
18.8% 0%
Legend: CD (Crohn Disease); UC (Ulcerative Colitis); ID (Indeterminate Colitis) 
Anti-TNF (antitumor necrosis factor)
Table 4: Therapy used for prevention of acute flares and maintenance of remission.
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